Dr. Nigel McCracken joined BerGenBio as Chief Scientific Officer in 2021, based in Oxford UK. He has more than 25 years of experience across Pharma, Biotech and CRO companies, most recently as the Chief Operating Officer concurrently holding the position as Senior VP Discovery and Early Development, at NuCana plc. Prior to this he was an Executive Board Member and Vice President of Translational Medicine at Debiopharm International. Dr. McCracken has worked in senior roles in the US and Europe, covering both preclinical and clinical development within a number of therapeutic areas such as cardiovascular, respiratory, rare disease, oncology, anti-infectives, metabolic disease, neuroscience, haematology and GI with both small and large molecules. He has broad experience recognising and evaluating high-quality science and also has a deep business and regulatory understanding and has spent the last 8 years working primarily in oncology with a focus on developing drug candidates in the area of targeted therapy and targeted delivery. Dr. McCracken has a BSc in Biochemistry and Pharmacology as well as a PhD in Biochemical Toxicology and an MSc in Clinical Pharmacology.
Selective AXL inhibitors
Footer
